MedTech growth concerns likely to overshadow Q3 results, Leerink says

Tandem Diabetes Care

09/10/2026 13:57

** Leerink Partners says it remains cautious about the MedTech sector ahead of Q3 earnings, citing a "somewhat murky" near-term backdrop
** Points to growing competition in certain markets, including cardiac devices and diabetes care, uncertain procedure volumes amid higher costs, weakening consumer sentiment and hospital budget pressure from rising interest rates
** "We suspect that even positive 3Q results in isolation could be overshadowed by lingering concerns regarding the earnings and growth backdrop for 2027 and beyond," brokerage says
** Says company-specific catalysts can help Medtronic MDT.N, Tandem Diabetes Care TNDM.O outperform broader sector headwinds
** Most cautious on PROCEPT BioRobotics PRCT.O and Insulet PODD.O, as slowing adoption trends and rising competition could lead to downward revisions to 2027 expectations, brokerage says

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))